Daiichi Sankyo Receives First Market Approval In Japan For LIXIANA(R) (Edoxaban), For The Prevention Of VTE After Major Orthopedic Surgery

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), announced today that the company has received its first marketing approval for LIXIANA� (JAN: Edoxaban Tosilate Hydrate, INN:edoxaban) 15 mg and 30 mg tablets, by the Ministry of Health, Labor and Welfare in Japan. Edoxaban, which is being developed solely by Daiichi Sankyo, is a once-daily oral anticoagulant that specifically, reversibly and directly inhibits the enzyme Factor Xa, a clotting factor in the blood...

Child Development Psychiatry Staying Healthy Stress